146 related articles for article (PubMed ID: 6415632)
1. Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma.
Faure N; Lemay A; Laroche B; Robert G; Plante R; Jean C; Thabet M; Roy R; Fazekas AT
Prostate; 1983; 4(6):601-24. PubMed ID: 6415632
[TBL] [Abstract][Full Text] [Related]
2. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
[TBL] [Abstract][Full Text] [Related]
3. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens.
Labrie F; Dupont A; Belanger A; Lacoursiere Y; Raynaud JP; Husson JM; Gareau J; Fazekas AT; Sandow J; Monfette G
Prostate; 1983; 4(6):579-94. PubMed ID: 6415630
[TBL] [Abstract][Full Text] [Related]
4. New hormonal therapy in prostate cancer: combined use of a pure antiandrogen and an LHRH agonist.
Labrie F; Dupont A; Belanger A; Lefebvre FA; Cusan L; Raynaud JP; Husson JM; Fazekas AT
Horm Res; 1983; 18(1-3):18-27. PubMed ID: 6411578
[TBL] [Abstract][Full Text] [Related]
5. New hormonal treatment in cancer of the prostate: combined administration of an LHRH agonist and an antiandrogen.
Labrie F; Dupont A; Belanger A; Lefebvre FA; Cusan L; Monfette G; Laberge JG; Emond JP; Raynaud JP; Husson JM; Fazekas AT
J Steroid Biochem; 1983 Jul; 19(1C):999-1007. PubMed ID: 6411995
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer.
Labrie F; Dupont A; Bélanger A; Emond J; Monfette G
Proc Natl Acad Sci U S A; 1984 Jun; 81(12):3861-3. PubMed ID: 6427777
[TBL] [Abstract][Full Text] [Related]
7. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
Labrie F; Dupont A; Belanger A; Cusan L; Lacourciere Y; Monfette G; Laberge JG; Emond JP; Fazekas AT; Raynaud JP; Husson JM
Clin Invest Med; 1982; 5(4):267-75. PubMed ID: 6819101
[TBL] [Abstract][Full Text] [Related]
8. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
Kuhn JM; Billebaud T; Navratil H; Moulonguet A; Fiet J; Grise P; Louis JF; Costa P; Husson JM; Dahan R
N Engl J Med; 1989 Aug; 321(7):413-8. PubMed ID: 2503723
[TBL] [Abstract][Full Text] [Related]
9. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
10. Combination of a GnRH agonist with an antiandrogen or bromocriptine in the treatment of prostatic cancer; slight potentiation of antigonadal effects.
Huhtaniemi I; Parvinen M; Venho P; Rannikko S
Int J Androl; 1991 Oct; 14(5):374-86. PubMed ID: 1839022
[TBL] [Abstract][Full Text] [Related]
11. Combined long-term treatment with an LHRH agonist and a pure antiandrogen blocks androgenic influence in the rat.
Lefebvre FA; Séguin C; Bélanger A; Caron S; Sairam MR; Raynaud JP; Labrie F
Prostate; 1982; 3(6):569-78. PubMed ID: 6296803
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer.
Bélanger A; Dupont A; Labrie F
J Clin Endocrinol Metab; 1984 Sep; 59(3):422-6. PubMed ID: 6086697
[TBL] [Abstract][Full Text] [Related]
13. The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review.
Raynaud JP; Bonne C; Moguilewsky M; Lefebvre FA; Bélanger A; Labrie F
Prostate; 1984; 5(3):299-311. PubMed ID: 6374639
[TBL] [Abstract][Full Text] [Related]
14. Additive inhibitory effects of treatment with an LHRH agonist and an antiandrogen on androgen-dependent tissues in the rat.
Séguin C; Cusan L; Bélanger A; Kelly PA; Labrie F; Raynaud JP
Mol Cell Endocrinol; 1981 Jan; 21(1):37-41. PubMed ID: 6259002
[TBL] [Abstract][Full Text] [Related]
15. Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.
St Arnaud R; Lachance R; Dupont A; Labrie F
J Clin Endocrinol Metab; 1986 Aug; 63(2):297-302. PubMed ID: 3522618
[TBL] [Abstract][Full Text] [Related]
16. The antiandrogen anandron potentiates the castrating effect of the LH-RH agonist buserelin in the rat.
Moguilewsky M; Tournemine C
Am J Clin Oncol; 1988; 11 Suppl 2():S148-51. PubMed ID: 3149454
[TBL] [Abstract][Full Text] [Related]
17. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
Lamberts SW; Uitterlinden P; de Jong FH
Cancer Res; 1988 Nov; 48(21):6063-8. PubMed ID: 2844399
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of efficacy and tolerability of Nilutamide and Buserelin in the treatment of advanced prostate cancer.
Migliari R; Scarpa RM; Campus G; De Lisa A; Zucca I; D'Atri M; Serra A; Usai E
Arch Ital Urol Nefrol Androl; 1991 Mar; 63(1):147-53. PubMed ID: 1830407
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of testicular androgen biosynthesis by chronic administration of a potent LHRH agonist in adult men.
Faure N; Lemay A
Arch Androl; 1985; 14(2-3):95-106. PubMed ID: 2933008
[TBL] [Abstract][Full Text] [Related]
20. Effect of 2-week combination therapy with the luteinizing hormone-releasing hormone (LHRH) agonist [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide and the antiandrogen flutamide on prostate structure and steroid levels in the dog.
Lacoste D; Dubé D; Bélanger A; Labrie F
Mol Cell Endocrinol; 1989 Dec; 67(2-3):131-8. PubMed ID: 2693158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]